drugset / Trial / NCT07099430

A Trial of LBL-024 Monotherapy, LBL-024 Combined With LBL-007 or Toripalimab in Patients With Advanced Melanoma

NCT07099430

Phase 1/2 Recruiting 200 enrolled Nanjing Leads Biolabs Co.,Ltd
RandomizedParallel-groupOpen-labelTreatment

Summary

This study is an open-label, multicenter phase Ib/II study to evaluate the efficacy and safety of LBL-024 monotherapy, LBL-024 in combination with LBL-007 or toripalimab in patients with advanced melanoma,To evaluate the preliminary efficacy and safety of LBL-024 monotherapy and combination therapy in patients with advanced melanoma.

Timeline

Start
2025-09-05
Primary completion
2027-10-30
Completion
2027-12-30

Drugs

EvaluationDrugModalityDoseRoute
Subject Alcestobart Monoclonal antibody Intravenous
Subject LBL-024 Unknown Intravenous
Subject Toripalimab Monoclonal antibody Intravenous

Indications